FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to neurology, and concerns rapid reduction of motor fluctuations in Parkinson's disease. That is ensured by administering levodopa into the pulmonary system in the form of fine particles by inhalation in the patients with Parkinson's disease having 3 to 4 OFF time episodes per day.
EFFECT: such method of introduction provides fast reduction of motor fluctuations and reduction of average daily OFF time in given specific group of patients due to earlier systemic action of levodopa in comparison with oral introduction.
21 cl, 11 dwg, 17 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | 2013 |
|
RU2685718C2 |
| REDUCTION OF INPATIENT VARIABILITY OF LEVODOPA CONCENTRATIONS IN BLOOD PLASMA | 2013 |
|
RU2682681C2 |
| METHODS OF PARKINSON'S DISEASE TREATMENT | 2004 |
|
RU2342929C2 |
| IMPROVED TRANSCUTANEOUS THERAPY SYSTEM FOR TREATING PARKINSON DISEASE CASES | 2002 |
|
RU2273477C2 |
| METHOD FOR TREATMENT OF PARKINSON'S DISEASE | 2014 |
|
RU2677278C2 |
| COMPOSITIONS FOR CONTINUOUS CONTROL OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2559083C9 |
| ULTRA LOW DENSITY INHALATION POWDERS | 2013 |
|
RU2670987C2 |
| COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2678839C2 |
| METHODS OF TREATING FUNGAL INFECTIONS | 2019 |
|
RU2820457C2 |
| METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
